VJOncology is committed to improving our service to you

GU Cancers 2020 | LEAP-011: first-line pembrolizumab plus lenvatinib for UC

VJOncology is committed to improving our service to you

Yohann Loriot

Yohann Loriot, MD, PhD, Gustave Roussy Institute & University of Paris-Saclay, Paris, France, discusses LEAP-011, a Phase III study of first-line pembrolizumab plus lenvatinib in patients with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter